Skip to NavigationSkip to content

personalised medicine

Making things personal: Roche and personalised medicine

Published on 13/08/19 at 11:42am

Ann Costello, Global Franchise Lead, Centralised Solutions at Roche Diagnostics, discusses the increasing need for a personalised approach to patient care to tackle today’s health challenges, and how big data and the interplay between pharmaceuticals and diagnostics are key to driving progress in this area.

Can you explain the core idea behind personalised medicine and why it is increasingly gathering traction?

Eli Lilly to buy Loxo Oncology in deal worth $8 billion

US firm Eli Lilly & Co today announced a definitive agreement for the acquisition of Connecticut-based company Loxo Oncology in a deal worth $8 billion.

Lilly will acquire biopharmaceutical firm Loxo, which is focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers, at a cost of $253 a share, representing a premium of about 68%.

First-ever study in the personalised treatment of rare cancers brings promising results

The first-ever trial to treat patients for rare cancers in a personalised manner based on the characteristics of their individual disease has wrought promising results, it has emerged.

The approach employed by the study differs from the traditional methodology which is generally determined by a cancer’s origin point, size and the stage of the disease, irrespective of the individual characteristics of the particular case. This has historically led to a huge discrepancy in success rates from patient to patient.

Breakthrough in personalised medicine as cancer vaccine shows results

The old adage that everyone is unique holds a lot of water when it comes to cancer treatment. Research has found that tumours tend to be distinctive to an individual, with their own specific mutations and profile. It is for this reason that even immunotherapies, such as the PD-1/PD-L1 wave of treatments, are incredibly important, but they do not necessarily work for everyone.

Roche posts positive mid-stage trial results for atezolizumab

Roche has more clinical trials of atezolizumab planned

A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm to begin plotting their conversations with regulators.

Atezolizumab is an immunotherapy drug that targets a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells.

Biomarkers Summit

Point of Care Diagnostics:

Biomarkers World Europe 2012

First personalised asthma drug shows promise

Roche’s personalised asthma drug lebrikizumab has met its primary end point in a phase II trial.

Lebrikizumab increased the level of lung function in adult asthma patients who were unable to control their disease on inhaled corticosteroids compared to placebo.

The drug, an injectable humanised monoclonal antibody, is designed to block interleukin-13 cytokine, a key contributor to the features of asthma.

The study found that interleukin-13 cytokine increases periostin, a protein that can be measured in the blood.

Developing Stratified Medicine in the UK - working towards a better future

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches